Today: Today, Axovant Sciences Ltd. (AXON) Receives “Outperform” Rating from Robert W. Baird

Today, Axovant Sciences Ltd. (AXON) Receives “Outperform” Rating from Robert W. Baird

Axovant Sciences Ltd. (NYSE:AXON)‘s stock had its “outperform” rating reiterated by research analysts at Robert W. Baird in a report issued on Friday. They currently have a $29.00 price objective on the stock. Robert W. Baird’s target price would suggest a potential upside of 104.37% from the stock’s current price.

AXON has been the subject of several other reports. JMP Securities reiterated an “outperform” rating and issued a $36.00 target price on shares of Axovant Sciences in a research note on Tuesday, August 16th. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $15.00 target price for the company in a research note on Tuesday, October 18th. HC Wainwright reiterated a “buy” rating on shares of Axovant Sciences in a research note on Wednesday, August 17th. Jefferies Group reiterated a “buy” rating and issued a $31.00 target price on shares of Axovant Sciences in a research note on Monday, September 26th. Finally, Evercore ISI reiterated a “buy” rating and issued a $29.00 target price on shares of Axovant Sciences in a research note on Friday, September 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $26.33.

Shares of Axovant Sciences (NYSE:AXON) traded up 0.50% during trading on Friday, hitting $14.19. The stock had a trading volume of 92,892 shares. The stock has a 50-day moving average of $13.09 and a 200 day moving average of $13.79. The firm’s market cap is $1.41 billion. Axovant Sciences has a 12-month low of $8.86 and a 12-month high of $21.30.

Several large investors have recently modified their holdings of AXON. Janus Capital Management increased its stake in shares of Axovant Sciences by 81.5% in the third quarter. Janus Capital Management now owns 2,532,890 shares of the company’s stock valued at $32,725,000 after buying an additional 1,137,455 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Axovant Sciences by 48.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 3,177,870 shares of the company’s stock valued at $44,490,000 after buying an additional 1,042,774 shares during the last quarter. Ghost Tree Capital LLC bought a new stake in shares of Axovant Sciences during the second quarter valued at $7,383,000. Citadel Advisors LLC increased its stake in shares of Axovant Sciences by 850.3% in the second quarter. Citadel Advisors LLC now owns 572,679 shares of the company’s stock valued at $7,353,000 after buying an additional 512,413 shares during the last quarter. Finally, VHCP Management II LLC bought a new stake in shares of Axovant Sciences during the first quarter valued at $4,932,000. 28.46% of the stock is owned by institutional investors.

About Axovant Sciences

Related posts

Leave a Comment